Back to resultsToxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Primary Purpose
Toxoplasmosis, Cerebral, HIV Infections
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pyrimethamine
Clindamycin
Sponsored by
About this trial
This is an interventional treatment trial for Toxoplasmosis, Cerebral focused on measuring Sulfonamides, Toxoplasmosis, AIDS-Related Opportunistic Infections, Pyrimethamine, Drug Therapy, Combination, Encephalitis, Acquired Immunodeficiency Syndrome, Clindamycin
Eligibility Criteria
Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy. Patients with other opportunistic infections or brain diseases are excluded. Patients with AIDS and cerebral toxoplasmosis.
Sites / Locations
- Palo Alto Med Foundation
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00002064
First Posted
November 2, 1999
Last Updated
June 23, 2005
Sponsor
Palo Alto Medical Foundation
1. Study Identification
Unique Protocol Identification Number
NCT00002064
Brief Title
Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Official Title
Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Study Type
Interventional
2. Study Status
Record Verification Date
June 1989
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Palo Alto Medical Foundation
4. Oversight
5. Study Description
Brief Summary
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Toxoplasmosis, Cerebral, HIV Infections
Keywords
Sulfonamides, Toxoplasmosis, AIDS-Related Opportunistic Infections, Pyrimethamine, Drug Therapy, Combination, Encephalitis, Acquired Immunodeficiency Syndrome, Clindamycin
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Pyrimethamine
Intervention Type
Drug
Intervention Name(s)
Clindamycin
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions are excluded:
Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.
Patients with other opportunistic infections or brain diseases are excluded.
Patients with AIDS and cerebral toxoplasmosis.
Facility Information:
Facility Name
Palo Alto Med Foundation
City
Palo Alto
State/Province
California
ZIP/Postal Code
94301
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
We'll reach out to this number within 24 hrs